Clinical trials: PSA, open to volunteers
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.
- Trial name
- OPTIMAS (NCT07216248)
- Testing
- relugolix + ARPI, Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI, relugolix or androgen deprivation therapy (ADT) + ARPI
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Utah
Prostate Cancer (Post Prostatectomy), Prostate Cancer (Adenocarcinoma)
Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer.
- Conditions
- Prostate Cancer (Post Prostatectomy), Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis), Prostate Specific Antigen
- Trial name
- PPSARP (NCT07516886)
- Testing
- Radical Prostatectomy
- Where
- Lithuania
- Volunteers
- 500 people
- Sponsor
- Lithuanian University of Health Sciences
Prostate Cancer Recurrent
PSMA-RLT in Biochemically Recurrent PCa
Prospective single-center one-arm phase II study in patients with prostate cancer and confirmed biochemical recurrence (BCR) with PSA of ≥ 0.2 ng/ml after radical prostatectomy (RP) or PSA > nadir + 2ng/ml after radiotherapy (RT)…
- Trial name
- NCT06220188
- Testing
- [177Lu]Lu-PSMA I&T
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Psoriasis Arthritis
A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis
The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as…
- Trial name
- STRIDE-PsA (NCT07417995)
- Testing
- Biologic or targeted synthetic DMARD (b/tsDMARD)
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- Royal United Hospitals Bath NHS Foundation Trust
Psoriatic Arthritis, Psoriasis
HIPPOCRATES Prospective Observational Study
HIPPOCRATES is an Innovative Medicines Initiative (IMI) funded EU Consortium established to address key unmet clinical needs in psoriatic disease.
- Trial name
- HPOS (NCT05858528)
- Testing
- PEST screening questionnaire
- Where
- United Kingdom
- Volunteers
- 25,000 people
- Sponsor
- University of Oxford
Systemic Lupus Erthematosus, Sjogren's Syndrome
Mass Spectrometry-based Immune Profiling in Autoimmune Diseases
Based on mass spectrometry flow method, this study analyzed the typing of new T, B, NK and DC cell subsets in peripheral blood of common autoimmune diseases and their correlation with disease activity, aiming at establishing an…
- Conditions
- Systemic Lupus Erthematosus, Sjogren's Syndrome, Inflammatory Myopathies, Systemic Sclerosis (SSc)
- Trial name
- NCT07188285
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Prostate Cancer, Risk Assessment
PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria
This study is a pilot trial that builds on findings from the validation of prostate cancer risk calculators in Nigerian men. The goal of the overall study is to improve the early detection of prostate cancer in a high-risk…
- Conditions
- Prostate Cancer, Risk Assessment, Clinical Decision Support Systems, Predictive Value of Tests
- Trial name
- PROACT (NCT07733440)
- Testing
- (a) Training and (b) Supported risk assessment
- Where
- Nigeria
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Ahmadu Bello University
Psoriatic Arthritis, Spondyloarthritis
The Corrona Psoriatic Arthritis and Spondyloarthritis (PsA-SpA) Registry
This prospective, non-interventional, research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for PsA-SpA in a cohort of patients cared for by rheumatologists across…
- Trial name
- NCT02530268
- Volunteers
- 5,000 people
- Sponsor
- CorEvitas
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received…
- Trial name
- EvoPAR-PR05 (NCT07711002)
- Testing
- Saruparib, Enzalutamide, Darolutamide
- Where
- 210 sites in United States, Austria and 19 more
- Volunteers
- 1,330 people
- Sponsor
- AstraZeneca
Cohort Study, Psoriatic Arthritis (PsA)
APACHE Cohort (A Psoriatic Arthritis CoHort)
Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease, belonging to the wide spectrum of spondyloarthritis, but with the particularity to be associated with personal psoriasis or familial psoriasis.
- Conditions
- Cohort Study, Psoriatic Arthritis (PsA), Recent Peripheral Arthritis
- Trial name
- APACHE (NCT03768271)
- Where
- 3 sites in France
- Volunteers
- 425 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostate Cancer Metastatic
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
PEACE-6 Poor Responders is an international, multicenter, open-label, controlled, randomized, phase III trial to evaluate the efficacy and safety of 177Lu-PSMA-617 when administered on top of the ongoing standard systemic…
- Trial name
- NCT06496581
- Testing
- 177Lu-PMSA-617, Standard of Care
- Where
- 25 sites in France
- Volunteers
- 500 people
- Sponsor
- UNICANCER
Systemic Lupus Erythematosus, Sjögren's Disease
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis
- Trial name
- NCT07791199
- Testing
- Deucravacitinib
- Volunteers
- 2,300 people
- Sponsor
- Bristol-Myers Squibb
Prostate CA, Prostate Cancer (Adenocarcinoma)
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
The goal of this clinical trial is to determine the safety and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate cancer (PCa) in…
- Conditions
- Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery
- Trial name
- NCT06631521
- Testing
- Darolutamide, Relugolix, Radical Prostatectomy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- AdventHealth
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases
The goal of this clinical trial is to assess the effectiveness of a disease activity guided dose reduction strategy of Janus kinase inhibitor (JAKi) compared to disease activity guided JAKi continuation in patients with…
- Conditions
- Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Axial Spondyloarthritis (AxSpA)
- Trial name
- REDO-JAK (NCT07160231)
- Testing
- JAKi dose reduction strategy, JAKi disease activity guided continuation of same dose strategy
- Where
- 7 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- Sint Maartenskliniek
Autoimmune Diseases, Rheumatoid Arthritis (RA)
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in…
- Conditions
- Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO)
- Trial name
- NCT07455578
- Testing
- S-4321
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Seismic Therapeutic AU Pty Ltd
Psoriatic Arthritis
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over…
- Trial name
- NCT07286058
- Testing
- Zasocitinib
- Where
- 78 sites in United States, Australia and 14 more
- Volunteers
- 1,182 people
- Sponsor
- Takeda
Prostate Cancer (Adenocarcinoma)
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach…
- Trial name
- TRIPLE-SWITCH (NCT06592924)
- Testing
- Abiraterone, Enzalutamide, Apalutamide
- Where
- 395 sites in United States, Canada and 2 more
- Volunteers
- 830 people
- Sponsor
- Canadian Cancer Trials Group
Psoriatic Arthritis
Sex and Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis
Sex and gender are important factors that influence treatment response in PsA. The goal of this multi-centre observational study is to understand how sex and gender influence response to advanced therapies in psoriatic arthritis…
- Trial name
- SAGE-PsA (NCT05954364)
- Where
- Canada
- Volunteers
- 540 people
- Sponsor
- Women's College Hospital
Spinal Cord Injury, Acute, Spinal Cord Injury at C4 Level With Complete Lesion
Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI
This study intends to evaluate the safety and exploratory efficacy of transplantation therapy using neural precursor cells (PSA-NCAM(+) NPC) derived from the human embryonic stem cell line for the treatment of paralysis and other…
- Conditions
- Spinal Cord Injury, Acute, Spinal Cord Injury at C4 Level With Complete Lesion, Spinal Cord Injury at C5-C7 Level With Complete Lesion
- Trial name
- SB-SCI-001 (NCT04812431)
- Testing
- Neural precursor cells derived from human embryonic stem cell line
- Where
- 2 sites in South Korea
- Volunteers
- 5 people
- Sponsor
- S.Biomedics Co., Ltd.
Psoriatic Arthritis (PsA)
Prevention of Psoriatic Arthritis Inflammation Through Digital Care: A Feasibility Mixed-Methods Study
This is an international, multicentre, feasibility mixed-methods, single-arm study evaluating the implementation of the iPROLEPSIS digital health promotion programme for adults with psoriatic arthritis (PsA) in real-world…
- Trial name
- PPIDC (NCT07772544)
- Testing
- iPROLEPSIS Digital Health Ecossystem
- Where
- 4 sites in Greece, Portugal
- Volunteers
- 72 people
- Sponsor
- Sociedade Portuguesa de Reumatologia